Sarepta (SRPT) PT Raised to $58 at Jefferies
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Jefferies analyst Gena Wang reiterated a Hold rating but lifted her price target on Sarepta Therapeutic (NASDAQ: SRPT) to $58.00 (from $50.00).
Wang commented, "Our deep analysis and DD with 4 payer KOLs suggest payers likely will regularly monitor real world benefit for Exondys 51 given its high price tag and a label stating no established clinical benefit. We expect net price in the range of $309-402K (assuming 70% compliance) with majority of pts likely covered by Medicaid. We raise PT to $58 to reflect updated launch assumptions and we believe stock is fairly valued."
Shares of Sarepta Therapeutic closed at $61.41 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Remains Sidelined on Capital One Financial (COF) Following EPS Beat
- Stifel Positive on Vertex (VRTX) as Triple Combo Moves Forward; PT Trimmed to $108
- Sprint (S) PT Raised to $4.50 at Jefferies
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change
Related EntitiesJefferies & Co, Gena Wang
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!